Sarcopenia Treatment Market - Growth, Trends, and Forecast (2019-2025)

The market is segmented by Treatment Type (Protein Supplement, Vitamin B12 Supplement, Vitamin D & Calcium Supplement an Others, Distribution Channel, and Geography

Market Snapshot

Sarcopenia treatement market_Pic 1
Study Period:

2016-2025

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

5.71%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Sarcopenia is the loss of skeletal muscle mass and function occurs with advancing age. Rising geriatric population is one of the key drivers of the studied market, as with growing age the chance of muscle weakness gets increased. The risk of disability is 1.5 to 4.6 times higher in older adults with sarcopenia than older adults without sarcopenia. In accordance with the data from World Population Prospects: the 2019 Revision, by 2050, 1 in 6 people in the world will be over age 65 (16%), up from 1 in 11 in 2019 (9%) and by 2050, 1 in 4 persons living in Europe and Northern America could be aged 65 or over. In 2018, the persons aged 65 or above outnumbered children under five years of age globally. The number of persons aged 80 years or over is projected to triple, from 143 million in 2019 to 426 million in 2050. This rising aging population trend hence hold the maximum potential to drive the market in near future also.

Scope of the Report

Sarcopenia is a term used to describe the loss of muscle mass, strength, and function that is associated with ageing. Currently, there are no FDA-approved medications for the treatment of sarcopenia. The effects of exercise and nutritional supplementation on patients with sarcopenia have been examined in numerous studies. In this report, the supplements (protein, vitamins and others) for treating sarcopenia, therefore, have been considered.

Key Market Trends

Protein Supplement is anticipated to grow with Considerable CAGR during Forecast Periods

Nutrition supplementation along with exercise is an effective strategy to decrease all the macronutrients can be used for energy production in human body, but only protein serves as a structural and functional compound in all organs and cells, which is why its demand is likely to increase in future. Proteins, especially rich in leucine, are the most effective branched-chain amino acid at stimulating muscle protein synthesis. Protein supplements help to retain the muscle mass muscle strength, and endurance. Recent evidence by Anne-Julie Tessier et al., supports a higher protein intake recommendation of 1.0–1.2 g/kg/day in healthy older adults; an evenly distributed mealtime protein intake or minimal protein per meal is considered to be beneficial.

Sarcopenia treatement market_Pic 2

To understand key trends, Download Sample Report

North America Dominates the Global Sarcopenia Treatment Market

As per the Population Reference Bureau, the number of Americans ages 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060, and the 65-and-older age group’s share of the total population will rise from 16% to 23%. About 45% of older adults in the United States are affected by sarcopenia, which is expected to increase as the population ages. In addition, there is a considerable economic burden of related healthcare expenditures for sarcopenia in the United States which is estimated to be USD 18.5 billion annually. Furthermore, the health awareness and active presence of major players are likely to drive the studied market growth in this region.

Sarcopenia treatement market_Pic 3

To understand geography trends, Download Sample Report

Competitive Landscape

The key manufacturers in the sarcopenia treatment market have been focusing on novel marketing and sales strategies to increase their product penetration. Along with that, rising inclination towards online distribution channel have been playing a vital role. Few of the key market players in the studied market are GlaxoSmithKline plc, Eli Lilly and Company, Nestlé S.A., Sanofi S.A., Bayer AG among others.

Major Players

  1. GlaxoSmithKline plc
  2. Nestle
  3. Sanofi
  4. Bayer AG
  5. Zydus Cadila

* Complete list of players covered available in the table of contents below

Sarcopenia treatement market_Pic 4

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Geriatric Population

      2. 4.2.2 Malnutrition and Vitamin Deficiency in Developing Countries

    3. 4.3 Market Restraints

      1. 4.3.1 Lower Development of New Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Treatment Type

      1. 5.1.1 Protein Supplement

      2. 5.1.2 Vitamin B12 Supplement

      3. 5.1.3 Vitamin D & Calcium Supplement

      4. 5.1.4 Others

    2. 5.2 Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Online Pharmacies

      4. 5.2.4 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 US

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 UK

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline plc

      2. 6.1.2 Nestle S.A.

      3. 6.1.3 Sanofi S.A.

      4. 6.1.4 Bayer AG

      5. 6.1.5 Novartis AG

      6. 6.1.6 Cadila Healthcare Ltd

      7. 6.1.7 Eli Lilly and Company

      8. 6.1.8 Five Prime Therapeutics

      9. 6.1.9 Radius Health

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information